Shattuck Labs (STTK) Depreciation & Amortization (CF) (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Depreciation & Amortization (CF) of $891000.0 for Q1 2026, down 4.81% year-over-year from $936000.0 in Q1 2025, and down 1.66% quarter-over-quarter from $906000.0 in Q4 2025.
Shattuck Labs (STTK) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $891000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 4.81% year-over-year to $891000.0; the TTM figure through Mar 2026 stood at $3.6 million (down 2.15% YoY), while the FY2025 annual figure was $3.7 million, down 3.68% from the prior year.
- Depreciation & Amortization (CF) declined to $891000.0 in Q1 2026 per STTK's latest filing, from $906000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.0 million in Q2 2023 and bottomed at $472000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $903647.1 across 5 years, with a median of $934000.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 145.79% — and 2024, when it fell 12.37%.
- Shattuck Labs' Depreciation & Amortization (CF) stood at $1.0 million in 2022, then retreated by 2.39% to $981000.0 in 2023, then dropped by 4.18% to $940000.0 in 2024, then decreased by 3.62% to $906000.0 in 2025, then decreased by 1.66% to $891000.0 in 2026.
- Business Quant data shows STTK's Depreciation & Amortization (CF) at $891000.0 in Q1 2026, $906000.0 in Q4 2025, and $900000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 800,000.00 |
| Jun 30, 2026 | 800,000.00 |
| Mar 31, 2026 | 891,000.00 |
| Mar 31, 2026 | 891,000.00 |
| Dec 31, 2025 | 906,000.00 |
| Dec 31, 2025 | 906,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 936,000.00 |
| Mar 31, 2025 | 936,000.00 |
| Dec 31, 2024 | 940,000.00 |
| Dec 31, 2024 | 940,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 974,000.00 |
| Mar 31, 2024 | 974,000.00 |